Mr Jackson joined Celator in October 2007 as head of commercial development. Mr Jackson has extensive experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing, and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems, Centocor (Johnson & Johnson), Eximias Pharmaceuticals and YM BioSciences.
Mr Jackson holds a BS in Pharmacy from the Philadelphia College of Pharmacy and Science and an MBA from the University of Notre Dame.
Joseph Mollica, chairman of Celator’s board of directors, said: “Scott’s senior management experience and commercial and clinical development knowledge will be extremely valuable to the organization as the company moves forward.”